Disability-Adjusted Life Year (DALY)
- Introduced by
- Christopher J. L. Murray and Alan D. Lopez (World Health Organization / World Bank)
- Year
- 1990
- Type
- Method
- Family
- population health metric
What does it do?
A DALY quantifies disease burden as the sum of years of life lost to premature death and years lived with disability.
Developed by the World Health Organization and World Bank in 1990 as part of the Global Burden of Disease (GBD) study, DALYs enable epidemiologists and public health planners to compare disease burden across populations, identify health priorities, and evaluate intervention impact. One DALY = one lost year of 'healthy' life; DALYs averted measure progress toward health goals.
The intuition behind the method
Diseases do two kinds of harm: they kill people (shortening life) and they disable people (reducing quality of life while alive). A metric for population health policy must capture both. Tuberculosis in a 30-year-old causes early death (YLL: lost years to age ~80) AND years of suffering before death (YLD). Polio causes permanent disability (high YLD) but lower mortality. DALYs unify these into one burden score. A nation with 1 million DALYs from malaria knows this is a major problem; if interventions can avert 100,000 DALYs/year for $10 million, the cost-effectiveness is $100 per DALY averted—a decision rule. WHO and most health ministries now use DALYs for priority setting, research funding, and reporting progress toward Sustainable Development Goals.
History
The concept originated in the World Bank's 1993 World Development Report, in which Murray and Lopez quantified disease burden to reframe development priorities around health (not just GDP). The first Global Burden of Disease study (1990) published in 1996, estimated DALYs for 100 diseases across eight regions. GBD 2000 and 2002 refined methods and data. GBD 2010 removed age weighting and adopted more inclusive disability weight elicitation (lay panels + patient data), responding to equity criticisms. GBD 2016 and 2019 incorporated newer epidemiological data, improved uncertainty quantification, and expanded cause lists to 369 diseases and injuries (2019 study published in The Lancet in 2020). Today, DALY is the de facto standard for international health reporting (WHO, UN SDG monitoring).
When to use it
When estimating population health burden (what diseases matter most?). DALY is the standard metric for WHO, national health ministries, and global health organizations (Gates Foundation, Gavi, etc.). Use when: comparing disease burden across countries or regions; tracking progress over time; prioritizing research funding; designing national health plans; evaluating public health interventions (vaccination programs, sanitation, health promotion); reporting health equity (DALYs by socioeconomic status or geography). Not appropriate for: assessing individual patient outcomes (use QALY); cost-benefit analysis at detailed clinical level; modeling non-health outcomes (employment, education).
Limitations and considerations
- Disability weights are subjective: lay panel valuations often differ from patient experience; assigning 0.4 weight to blindness may not reflect how blind persons value their quality of life.
- Discounting and age weighting are controversial: standard 3% discount rate is arbitrary; age weighting (pre-2010 GBD) undervalued elder health, now widely criticized as ageist.
- DALYs assume disease duration and disability are fixed: does not account for heterogeneity within diagnoses (some asthmatics severely disabled, others minimally) or natural remission.
- Comorbidity not explicitly modeled: a person with both diabetes and depression is counted as two separate DALY streams; interaction effects ignored.
- Large uncertainty in low-income countries: sparse epidemiological data leads to reliance on modeling and assumptions; DALY estimates carry wide confidence intervals, yet reported as point estimates.
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Unifies mortality and morbidity into one metric, enabling direct comparison of burden from fatal vs disabling diseases on a single priority scale.
- Grounded in epidemiological data: DALYs are derived from observed incidence, prevalence, and mortality, not theoretical assumptions.
- Globally standardized: GBD study provides comparable DALY estimates across 195 countries, facilitating international benchmarking and equity analysis.
- Supports evidence-based policy: national health ministries use DALY burden rankings to allocate budgets, design guidelines, and communicate health priorities to public and donors.
Applications
- Global Health Observatory (WHO): publishing country health profiles ranked by DALY burden, informing ministerial health planning and donor priorities.
- Disease-specific funding priorities: Global Fund, Gates Foundation, and GAVI use DALY burden to allocate grants for HIV, tuberculosis, malaria, vaccine-preventable diseases in low-income countries.
- National health plans: countries use GBD estimates to design strategic health plans; e.g., India's health ministry identifies TB and maternal mortality as top DALY drivers, justifying intensive national programs.
- Intervention evaluation in public health: cost-effectiveness threshold comparison (e.g., bed nets cost $5–$10 per malaria DALY averted, well below WHO threshold, justifying scale-up).
- Research priority setting: WHO ranks disease research needs by DALY burden; neglected tropical diseases with high DALY but low profit margin receive dedicated research funding from global bodies.
How it works
How it works
Step 1: Establish baseline epidemiological data—incident cases, deaths, duration of illness, age/sex distribution. Data sources: national vital statistics (mortality), hospital discharge data, disease registries (cancer, injury), population-based surveys (disability prevalence), sentinel surveillance (infectious diseases), published literature (estimates for data-poor regions). Step 2: Define disability weights for each condition. GBD expert panels and lay population surveys rate health states (e.g., asymptomatic HIV, treated hypertension, severe depression) on a scale 0–1. A paralyzing spinal cord injury might be 0.55; headache 0.01; dementia 0.73. Weights account for symptom severity, mobility, cognition, and social functioning. Step 3: Obtain or estimate life expectancy tables (WHO standard or country-specific). GBD uses a reference life expectancy (e.g., Japanese female life expectancy as standard, with age-dependent values).
Formula
Ascertain disease incidence, prevalence, and mortality rates from vital statistics, disease registries, epidemiological surveys, and facility data. Classify conditions by disability weight (0 = no disability, 1 = equivalent to death) using expert panels and population surveys.
Formula: DALY = YLL + YLD. YLL (Years of Life Lost) = Σ(deaths at age × life expectancy at that age). Example: 100 deaths from malaria, average age 5 years, life expectancy 70 years → YLL = 100 × (70 − 5) = 6,500 years. YLD (Years Lived with Disability) = Σ(number of people with condition × disability weight × average duration). Example: 10,000 people with acute dengue (average duration 2 weeks = 0.038 years, disability weight 0.197) → YLD = 10,000 × 0.197 × 0.038 = 74.6 years. Total DALY = 6,500 + 74.6 = 6,574.6 years. Standard practice: discount future years at 3% annually and apply age weighting (valuing productive adult years higher than childhood/elderly), though GBD 2010+ removed age weighting after equity critique.
Formula
DALY = YLL + YLD, where YLL (Years of Life Lost) = deaths × standard life expectancy at age of death; YLD (Years Lived with Disability) = prevalence × disability weight × duration in years.
A disease's DALY burden indicates priority for intervention. High-burden diseases (HIV, tuberculosis, malaria, depression, injury) warrant investment in prevention, treatment, and research. Stratify by geography: Sub-Saharan Africa has highest malaria DALY burden; high-income countries have high burden from cancer, cardiovascular disease, mental health. By age: childhood infections dominate YLL in low-income settings; non-communicable diseases dominate in aging populations. Trend over time: declining malaria DALYs in regions with scale-up of bed nets and treatment; rising cancer DALYs globally due to aging and smoking. Intervention evaluation: if a malaria control program prevents 50,000 cases/year at 0.4 disability weight for 3 months = roughly 5,000 DALYs averted/year. Cost-effectiveness = cost per DALY averted (compared to WHO threshold ~$30,000–$150,000 per DALY averted, varying by country GDP).
Formula
Sum DALYs across all conditions and age groups for population or disease-specific burden estimate. Compare disease burden across time (trends), geography (country/region comparisons), or age cohorts. Lower DALYs = better health; DALYs averted by intervention = intervention effectiveness. Use to prioritize public health investment and research funding.
Common pitfalls
- Confusing DALY with QALY: DALYs measure burden (0 = perfect health, higher = sicker); QALYs measure benefit (1 = perfect health, lower = sicker). DALY averted ≈ QALY gained, but they are not interchangeable in all contexts (different time horizons, populations).
- Using outdated disability weights: GBD disability weights have evolved (2010, 2016, 2019 revisions); comparing DALYs across different GBD years can be misleading without adjustment.
- Ignoring uncertainty: reporting point estimates (e.g., 100 million DALYs) without confidence intervals; GBD publishes 95% UI, which can be large in low-data regions.
- Applying global GBD estimates to local decisions: global average disability weight for depression may not reflect local treatment access or patient values; whenever possible, use local epidemiological data.
- Overlooking social determinants: DALY burden is a summary statistic; high malaria DALYs in country X indicate a need for investigation into water access, poverty, and education (root causes not captured in DALY itself).
Frequently asked questions
What is the standard life expectancy used in DALY calculations?
GBD 2010 and later versions use a reference life expectancy based on lowest observed death rates at each age globally (essentially Japanese female life expectancy, with adjustments for recent improvements). This ensures consistent YLL calculation across countries, regardless of local life tables. This is a methodological choice to enable comparability; some high-income countries use local life expectancy.
How are disability weights determined for new or rare diseases?
GBD expert panels conduct systematic reviews of clinical literature and patient reports, then weight health states. For very rare conditions, weights may be inferred from similar conditions or elicited through limited surveys. Uncertainty is high; confidence intervals are wide. As more evidence accumulates (patient registries, published health utility studies), weights are revised.
Why does GBD 2010 remove age weighting when earlier versions used it?
Age weighting privileged 'productive years' (15–50), assigning lower weight to childhood and elderly. This was criticized as ageist and contrary to human rights principles (a child's life is not worth less). GBD 2010 and later versions use uniform age weighting (all years of healthy life valued equally), aligning with ethical norms and social preferences in most high-income countries.
How are comorbidities handled if a person has multiple conditions?
Standard DALY approach sums YLD contributions from each condition separately. This can lead to double-counting (a person with diabetes + depression counted as two YLD streams). More sophisticated approaches use joint disability weights or hierarchical modeling (e.g., the worse disability takes precedence), but these are not standard in GBD. Users should note that DALY sums assume independence.
What is the difference between incidence-based and prevalence-based DALYs?
Incidence-based: DALY counts a cohort from disease onset until recovery/death (follows incident cases forward). Prevalence-based: counts current persons with disease, multiplying by annual disability weight. Incidence-based DALYs align with cohort follow-up and interventions (e.g., vaccination prevents future DALYs). Prevalence-based DALYs reflect current healthcare burden. GBD primarily uses prevalence-based for YLD, but outcomes vary by disease.
Can DALYs be negative, or can an intervention create DALYs?
No. DALYs are always ≥0; higher DALYs = more burden. An intervention cannot create DALYs (it averts them or has no effect). However, an intervention with adverse effects (e.g., medication side effects) can reduce the DALY averted or even increase overall burden if side effects outweigh benefits.
Related methods
Sources
Murray, C. J., Lopez, A. D., & Jamison, D. T. (1994). The Global Burden of Disease in 1990: Summary Results, Sensitivity Analysis, and Future Directions. In C. J. Murray & A. D. Lopez (Eds.), Global Burden of Disease and Injury. Cambridge: Harvard University Press.
Open publication referenceCopied.Global Burden of Disease Study 2019 Collaborators. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 396(10258), 1204-1222.
Open publication referenceCopied.Mathers, C. D., Vos, T., & Lopez, A. D. (2003). The Burden of Disease and Injury in Australia. Public Health Division, Department of Health and Ageing, Australian Government.
Open publication referenceCopied.